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Abstract
Background—Although systemic chemotherapy in patients with unresectable metastatic
colorectal cancer (mCRC) is palliative in nature, some patients experience long-term remission
beyond 5 years consequent to treatment with chemotherapy alone.
Patients and Methods—We reviewed clinical data from 32 prospective North Central Cancer
Treatment Group chemotherapy trials in mCRC that enrolled patients from 1972 to 1995.
Metastatic CRC was verified histologically. Excluded from analyses were patients who withdrew
consent to the study, enrolled in > 1 study, were ineligible, or had major protocol violations. We
defined patients with survival beyond 5 years from the initiation of systemic treatment of mCRC
as long-term survivors (LTS).
Results—A total of 36 of 3407 (1.1%) patients were LTS. A total of 13 patients (0.4%) are
without evidence of disease or disease progression > 5 years from cessation of last chemotherapy,
with a median follow-up of 10.6 years (minimum, 7.6 years). Long-term survivors were more
likely to have received 5-fluorouracil (5-FU)–based treatment (33 of 2503 [1.3%]) as opposed to
other, less effective therapy (3 of 904 [0.3%]), suggesting that the chemotherapy played an
important role among LTS (P = .01). Clinical characteristics of LTS were similar to the overall
population in terms of age, sex, performance status, and tumor grade.
Conclusion—This study establishes a baseline for long-term outcomes of mCRC in the era
when effective treatment was limited to 5-FU. With the development of improved systemic
therapy for mCRC, cure without salvage surgery might be possible for a small, but important
number of patients. Clinical trials should follow patients for > 5 years to document the long-term
outcomes.
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Introduction
Metastatic colorectal cancer (mCRC) is the second leading cause of cancer death in the
United States. Randomized trials of best supportive care versus chemotherapy have
established the benefit of cytotoxic treatment in terms of survival and quality of life.1–4
First-line chemotherapy with 5-fluorouracil (5-FU)–based regimens is considered standard
practice. Before the introduction of oxaliplatin, irinotecan, and other novel molecularly
targeted signal transduction inhibitors, median survival was 12–15 months from the time of
diagnosis of metastasis.5,6 Long-term survival in mCRC can be achieved in a minority of
patients with a multimodal treatment approach, particularly when all known disease sites are
resected.7–15 There are little data whether long-term survival with systemic chemotherapy
alone is observed. Most of the reports in the literature regarding this subject are anecdotal or
short case series. Massacesi et al have published a nomogram using clinical information
collected prospectively from 1057 patients with advanced CRC to predict for long-term
survival.15 However, their study was limited by several factors. The median follow-up
duration (38 months) and the definition of long-term survival as > 2 years were inadequate
to distinguish patients who have indolent disease from, and to restrict analysis to, patients
who are truly long-term survivors (LTS) as a result of systemic therapy alone. Moreover,
long-term survival has conventionally been defined (somewhat arbitrarily) by at least 5-year
survival rates after cancer diagnosis.16 Colorectal cancer has a variable course, and in some
patients, the ‘natural course of disease’ metric of 5-year survival cannot be used as a
surrogate for ‘cure’ rate.17,18 Moreover, Massacesi et al included patients who underwent
surgery and radiation therapy for curative intent of metastases. Perez et al included 5-year
and 10-year long-term outcomes in their recent report; however, their study likewise
included patients who underwent surgical resection for metastatic disease.19
Long-term survival rates are widely used outcome measures for cancer patients to monitor
progress in cancer care over time. We thus undertook this study to determine the frequency
and clinical characteristics of patients with mCRC who had long-term survival > 5 years
after treatment with pre-1995 systemic chemotherapy alone. This information will be useful
for subsequent studies on the changes in the trends of survival outcomes with newer
regimens. Moreover, the ability to identify this group of patients might help direct treatment




Institutional review board approval was granted before conducting this study. We reviewed
the database established for all phase II and III chemotherapy trials for mCRC conducted by
the North Central Cancer Treatment Group (NCCTG) from the mid-1970s to the early 1990s
to identify LTS. We defined LTS as patients who are alive > 5 years after initial treatment of
mCRC, without the benefit of surgical resection. Patients must have been eligible for and
treated on at least one of the aforementioned NCCTG mCRC chemotherapy trials. Baseline
laboratory and pathology reports, performance status (PS), treatment duration, treatment
response, disease-free interval, and survival data are contained in these records. All patients
had histologic or cytologic confirmation of mCRC. However, protocols do not mandate that
all anatomic sites of metastases require pathologic confirmation. Patient study records were
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individually reviewed for each LTS to confirm survival and determine whether surgery was
performed for mCRC.
Staging and measurement of disease was by computed tomography (CT) scan and, if
appropriate, other radiologic investigations or endoscopy. Patients’ PS was graded according
to the Eastern Cooperative Oncology Group scale and recorded at the initial consultation.
Response to systemic therapy was classified using the World Health Organization objective
response criteria.
Chemotherapy
The various chemotherapy regimens used in the 32 prospective phase II and III NCCTG
chemotherapy trials for mCRC, both first-line and subsequent therapies, included in this
analysis are shown in Table 1.
Statistics
Overall survival (OS) was defined as the time from study registration to death from any
cause. Because of the variety of treatments used, and that only a small number of LTS were
identified, this study is primarily descriptive in nature. Univariate association between LTS
status and baseline demographics were performed using a t test for age and duration of




There were 3811 patients treated on 32 NCCTG clinical trials for mCRC. A total of 396
patients either withdrew consent to the study, enrolled in > 1 study, were ineligible, or had
major violations and were removed from further analysis. Eight LTS patients had surgical
resection of mCRC and were also excluded. Of the remaining 3407 patients, 2503 patients
were treated with 5-FU–based regimens; 904 patients received other chemotherapy. Median
follow-up for living patients was 9.9 years.
Of the 3407 patients, 3403 (99.9%) were followed until their demise or for > 5 years. Figure
1 presents the Kaplan-Meier estimate of OS; Table 2 presents the estimated survival rate by
year. Thirty-six patients (1.1%) survived > 5 years with chemotherapy alone. Thirteen
patients (0.4%) had no evident site of disease involvement for > 5 years from last treatment.
Nineteen of the 36 patients (53%) received at least two lines of chemotherapy, to a
maximum of 3 salvage regimens. Five of the 36 patients (14%) developed a metachronous
colorectal malignancy > 12 months from initial diagnosis of colon cancer, one of which was
diagnosed while the patient was receiving systemic therapy. Characteristics of LTS are
shown in Table 3.
A total of 19 deaths were documented at the last follow-up among the 36 LTS. A total of 14
patients and 3 patients died of mCRC between 5–8 years and between 8–10 years of follow-
up, respectively. One patient died of a cerebrovascular event 9 years after her initial
diagnosis of metastatic disease. She had been off systemic cancer therapy for approximately
3 years before her demise. Another patient was off treatment and deemed to have no evident
site of disease involvement (NED) for 19 years before her death, which occurred 23 years
after the diagnosis of mCRC. The cause of this patient’s death was unknown.
A total of 13 patients were without evidence of disease > 5 years from cessation of last
chemotherapy until death or the last follow-up (range, 7.6–23 years).
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Comparison of Long-Term Survivors with Control Patients with Metastatic Colorectal
Cancer
The relationship between LTS status and patient characteristics was examined on the subset
of patients treated on the five largest trials where the variables of interest were consistently
collected; this included 35 of the 36 LTS (Table 3). Mean age, PS, sex, primary tumor
location, and tumor grade did not differ significantly among patients with LTS from the
general treatment mCRC population/ control population.
Effect of Chemotherapeutic Agent
A total of 33 patients (1.3%) were LTS among the 2503 patients treated with 5-FU based
regimens. Three patients (0.3%) were LTS among the 904 patients treated with other non–5-
FU-based regimens. Patients receiving 5-FU–based regimens were more likely to be LTS (P
= .01). Twelve of 13 patients deemed to have NED status received 5-FU–based therapy.
Discussion
We performed a review of data from 32 clinical trials in mCRC enrolling 3811 patients to
identify the subset of patients with long-term survival > 5 years from initiation of therapy for
their advanced disease. To our knowledge, this study presents the largest group of LTS with
the longest follow-up data among patients with mCRC treated with systemic chemotherapy
alone. Because all patients had clinically evident biopsy-proven metastases and PET scans
were not incorporated in the staging of disease, our observations were not likely to be
subject to stage migration bias.
Although the median survival of patients with mCRC was approximately 1 year using
pre-1995 chemotherapy regimens, in our experience approximately 1.1% have an unusually
long survival after diagnosis and treatment with systemic chemotherapy alone; rarely, the
disease appears to be “cured.” The clinical characteristics of the group of LTS do not readily
explain why most patients with mCRC who have a similar constellation of features die faster
than LTS. The use of 5-FU–based regimen was independently associated with LTS. In fact,
with the availability of newer drugs such as oxaliplatin, preliminary evidence suggests that
the ability of systemic treatment alone to attain complete tumor responses in mCRC can
result in durable survival outcomes comparable to those seen among patients who undergo
additional locoregional therapies such as surgical resection of residual operable
metastases.20
The phenomenon of LTS among patients with mCRC is not widely appreciated because 5-
year survival rate among patients with distant metastases is approximately 1%. However, the
fact that patients with mCRC can survive in the ‘long tail’ of the survival distribution attests
to the underlying heterogeneity of tumor behavior and response to treatment. Although
rapidly-growing CRC has been reported, tumor growth of CRC in terms of tumor volume
doubling time is characteristically deemed slow in relation to other tumors.17,21 Patients
with metastatic disease have been reported to live for > 5 to 10 years, without any specific
therapy.22,23 Indeed, our own study showed that half of the patients who were LTS could
not be considered ‘cured’ of their disease because they ultimately died from cancer.
However, the remaining half of the group of LTS apparently may be considered cured
because the majority do not have any evident site of metastatic involvement after therapy.
The concept of conditional survival on prognosis might thus be applicable for LTS among
patients with metastatic disease, albeit in a limited sense, as it does for earlier stages of
CRC.24 Similar observations of long-term survival have been reported in patients with
metastatic breast cancer.25–28 A limitation inherent in this study lies in the variability/
reproducibility in the determination of tumor response evaluation in the clinical setting,29
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which partly resides in the ‘overclassification’ of imaging abnormalities as metastatic
disease when they are in fact nonmalignant. Another limitation in this study is that inherent
tumor biology is unknown; thus, the contribution of this variable to treatment-associated
long-term survival cannot be established and is a potential confounding factor,30 and an
imbalance of favorable prognostic markers up front might have skewed the clinical course of
patients that led to our observation of more LTS in patients receiving 5-FU than non–5-FU
therapies. Hence, the importance of tissue banking in conjunction with large phase III trials
cannot be overemphasized as technological improvements in molecular analyses of banked
specimen will allow us to longitudinally study and identify prognostic features associated
LTS separate from predictive markers of treatment response. Ultimately, long-term survival
is the result of effective therapy as well as favorable intrinsic tumor biology, and research
endeavors should continue to improve the former and understand the latter.
Conclusion
In the 5-FU era, approximately 1.1% of patients with histologically confirmed, unresected
mCRC survived 5 years after initiation of chemotherapy. Approximately 1 of every 200
patients appear to have been potentially cured of mCRC by systemic chemotherapy alone.
Long-term survivors were similar to the general treatment mCRC population with respect to
age, PS, sex, tumor grade, and sites of metastatic disease. Treatment with a 5-FU–based
regimen was an important determinant in the outcome among patients with LTS. Future
clinical trials of chemotherapy of mCRC should track the frequency of LTS to determine the
number of patients who are LTS with newer therapies. Further investigations are needed to
characterize the distinct molecular features of LTS, knowledge of which will be of vital
interest in treatment decision-making and in endeavors to improve ‘tailored’ therapies
appropriate to individual patients.
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Kaplan-Meier Estimate of Overall Survival
Dy et al. Page 8

























Dy et al. Page 9
Table 1
List of Protocols and Patient Enrollment Included in This Analysis











701801 Methyl CCNU, 5-FU, and ifosfamide 76 1 0
701831 (A) 5-FU, doxorubicin; (B) 5-FU, vincristine, and methyl CCNU 109 0 0
701833 (A) Combined 5-FU, methyl CCNU, and vincristine; (B) 5-FU
and methyl CCNU; (C) 5-FU and CAC platinum with a controlled
evaluation of MER as an adjuvant immunostimulant
158 1* 0
754601 VP-16 (NSC-141540) and galactitol (NSC-132313) 59 0 0
754604 Triazinate (TZT, Baker’s Antifol) 29 0 0
764601 Pyrazofurin (PRZF) 37 0 0
764602 Cytosine arabinoside (Ara-C) 32 1* 0
764802 (A) Tegafur; (B) 5-FU, methyl CCNU and TZT; (C) 5-FU, methyl
CCNU, and ICRF-159; (D) 5-FU, methyl CCNU
202 0 0
774601 Maytansine 31 0 0
774603 Hycanthone (NSC-14982) 30 0 0
784601 Cyclophosphamide, doxorubicin, and cis-platinum 30 0 0
784602 Chlorozotocin 66 0 0
784651 (A) 5-FU plus TZT; (B) 5-FU plus ICRF-159; (C) methyl CCNU
plus ICRF-159; (D) methyl CCNU plus TZT; (E) ICRF-159 plus
TZT; (F) 5-FU alone
248 0 0
794601 Indicine-N-Oxide (NSC 132319) 30 0 0
794602 N-(Phosphonacetyl)-L-Aspartate (PALA) 31 0 0
794605 6-Thioguanine 31 0 0
804601 L-Alanosine 30 0 0
804602 Aziridinylbenzoquinone (AZQ; NSC 182986) 31 0 0
804605 6-Diazo-5-Oxo-L-Norleucine (DON, NSC-7365) 30 0 0
804606 9–10 Anthracenedicarboxaldehyde bis (4,5-dihydro-1H
imidazol-2-yl) hydrazone dihydrochloride (CL216,942; ADAH)
31 0
804651 (A) 5-FU; (B) 5-FU plus TDR; (C) 5-FU plus PALA; (D) 5-FU
plus LV; (E) 5-FU plus methyl CCNU plus vincristine plus
streptozotocin
347 5 1
814602 BCNU and PALA 30 0 0
814603 PALA (NSC-224131) and L-Alanosine (NSC-153353) 31 0 0
824601 PALA/5-FU/Thymidine 44 0 0
834601 High-dose cis-platinum in combination with loading course 5-FU 33 0 0
834652 (A) 5-FU plus methotrexate; (B) 5-FU plus LV (high dose); (C) 5-
FU plus LV
703 12 5
844601 Tricyclic Nucleoside 5′-Phosphate (NSC 280594) 31 0 0
854601 Recombinant human interferon-′ 36 0 0
874601 Intravenous 6-Thioguanine 15 0 0
874652 Somatostatin 263 4 2
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894652 (A) 5-FU plus the l-isomer of LV; (B) 5-FU plus oral (d,l) LV;
(C) 5-FU plus intravenous (d,l) LV
942 21 8
904601 5-FU and levamisole 15 0 0
*
Same patient, enrolled to studies sequentially after disease progression.
Abbreviations: 5-FU = 5-fluorouracil; LV = leucovorin
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Table 2
Estimated Survival Rate by Year
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Table 3
Characteristics of Long-Term Survivors*
Characteristic Non-LTS (N = 2334) Patients Surviving > 5Years (N = 35)
P Value Comparing
Non-LTS to LTS
NED at Last Evaluation
(N = 12)
Age, Years
 Mean 63 62 .7037 59
 Median 64 65 – 65
 Range 14–90 32–80 – 32–74
Sex (%)
 Female 1029 (44) 11 (31) .1696 6 (50)
 Male 1305 (56) 24 (69) – 6 (50)
Disease Grade (%)
 1–2 1646 (71) 22 (63) .2538 6 (50)
 3–4 633 (27) 13 (37) – 6 (50)
 Missing 55 (2) – – –
Performance Score (%)
 0 861 (37) 18 (51) .2377 6 (50)
 1 1093 (47) 13 (37) – 3 (25)
 2–3 379 (16) 4 (11) – 3 (25)
 Missing 1 (0) – – –
Primary Site (%)
 Left 929 (40) 16 (46) .1595 1 (8)
 Right 760 (33) 12 (34) – 7 (58)
 Rectal 399 (17) 7 (20) – 4 (33)
 Other 246 (11)† – – –
Metastatic Site‡
 Liver – 17 – 7
 Lung – 6 – 2
 Lymph node – 6 – 1
 Intra-abdominal – 12 – 5
 Pelvis – 3 – 1
Response (%)
 CR 31 (1) 7 (20) < .0001 5 (42)
 PR 292 (13) 3 (9) – 1 (8)
 SD 1657 (71) 25 (71) – 6 (50)
 PD 302 (13) – – –
 Unknown 52 (2) – – –
Duration of Treatment, Days
 Mean 154 855 < .0001 1058
 Median 92 552 – 634
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Characteristic Non-LTS (N = 2334) Patients Surviving > 5Years (N = 35)
P Value Comparing
Non-LTS to LTS
NED at Last Evaluation
(N = 12)
 Range 1–1611 1–3153 – 1–2915
*
Studies 784651, 804651, 834652, 874652, 894652.
†
Contains colon not otherwise specified (239), intestinal (1), cervix (2), and ovary (4).
‡
Metastatic site information from chart reviews; and this was not performed for non-LTS patients.
Abbreviations: CR = complete response; LTS = long-term survivors; NED = no evident site of disease involvement; PD = progressive disease; SD
= stable disease
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